Petaluma, United States
Spectrum Antimicrobials, founded in 2016 and headquartered in the United States, is a biotechnology firm dedicated to pioneering infection-control solutions. Their novel antiseptic and disinfectant formulations are positioned to become transformative in health and wellness sectors.
The company boasts two groundbreaking broad-spectrum, non-antibiotic chemistries aimed at combating a range of infections caused by viruses, bacteria, fungi, and molds. This innovation is crucial in fighting infections in critical areas such as wounds, surgical sites, and body cavities without promoting antibiotic resistance.
With potential cost-saving implications on over $30 billion spent annually in the U.S. alone on antibiotic-resistant infections, Spectrum Antimicrobials presents a compelling opportunity. Their platforms target the replacement of outdated chemistries, addressing serious health challenges that contribute to over 100,000 annual deaths.
The company last secured a $7.70M Early VC investment on 01 April 2021, underscoring investor confidence in its innovative solutions.
